Clinical bottom line
Antisense oligonucleotide (ASO) therapies represent a promising, targeted approach for certain rare inherited retinal dystrophies (IRDs), offering potential to modulate gene expression and correct splicing defects. Early-phase clinical trials and preclinical studies demonstrate proof-of-concept efficacy in specific genotypes, particularly those with well-characterized splicing mutations. However, clinical utility remains limited by delivery challenges, variable durability of effect, and incomplete understanding of long-term safety. ASO therapy should be considered an emerging option within a precision medicine framework, warranting careful patient selection and ongoing monitoring.
What the evidence shows
Inherited retinal dystrophies encompass a genetically heterogeneous group of rare disorders characterized by progressive photoreceptor degeneration and vision loss (Yerxa et al., 2022). ASOs are short, synthetic nucleic acid sequences designed to bind RNA transcripts and modify splicing or reduce toxic protein expression. This mechanism enables allele-specific targeting, which is particularly relevant for autosomal dominant IRDs caused by gain-of-function or dominant-negative mutations (Xue et al., 2020).
Clinical and preclinical evidence supports the feasibility of ASO therapy in IRDs. For example, Xue et al. (2020) reviewed multiple ASO candidates in clinical trials targeting mutations in genes such as USH2A and CEP290, which cause retinitis pigmentosa and Leber congenital amaurosis, respectively. Early-phase trials have reported stabilization or modest improvement in retinal function and visual acuity, although sample sizes remain small and follow-up durations limited.
Nichols et al. (2024) provide a comprehensive overview of novel therapies for IRDs, highlighting ASOs as a leading gene-based strategy alongside gene augmentation and genome editing. They emphasize that ASOs can be delivered via intravitreal injection, a less invasive route compared to subretinal gene therapy, potentially facilitating repeated dosing. Stieger et al. (2017) further note that pediatric patients with early-onset IRDs may particularly benefit from ASO approaches due to the potential to intervene before irreversible photoreceptor loss.
Despite encouraging signals, challenges remain. ASO delivery to retinal cells is hindered by barriers such as the inner limiting membrane and retinal pigment epithelium, limiting bioavailability. Li et al. (unrelated to retinal disease but informative on ASO delivery) demonstrate that polymer conjugation can enhance ASO stability and tissue penetration, a strategy that may be translatable to ocular applications. Moreover, the durability of ASO effects is variable, often requiring repeated administration, which raises concerns about cumulative toxicity and patient adherence.
Caveats and uncertainty
The evidence base for ASO therapy in IRDs is still evolving, with most data derived from early-phase clinical trials or animal models. Larger, controlled studies with longer follow-up are needed to define efficacy endpoints, optimal dosing regimens, and safety profiles. The heterogeneity of IRDs complicates generalization; ASOs are mutation-specific, so broad applicability across diverse genotypes is limited.
Long-term safety concerns include immune reactions, off-target effects, and retinal toxicity, which remain incompletely characterized. The intravitreal route, while less invasive, may not achieve sufficient ASO concentrations in outer retinal layers for all mutations. Additionally, the cost and accessibility of ASO therapies pose practical barriers to widespread clinical implementation.
Finally, current ASO candidates predominantly target splicing defects or toxic gain-of-function mutations; recessive loss-of-function IRDs may require complementary approaches such as gene augmentation or editing.
How this may change practice
Clinicians managing patients with IRDs should be aware of ASO therapies as an emerging precision medicine option, particularly for those with confirmed pathogenic splicing mutations amenable to ASO modulation. Genetic diagnosis with detailed mutation characterization is essential to identify suitable candidates.
Referral to specialized centers conducting ASO clinical trials or offering compassionate use programs may provide access to novel treatments. Multidisciplinary care teams should incorporate genetic counseling to discuss the experimental nature, potential benefits, and limitations of ASO therapy.
Ongoing monitoring of visual function and retinal structure is critical to assess therapeutic response and detect adverse effects. As evidence matures, ASO therapies may become integrated into standard care algorithms, complementing existing gene therapy and supportive interventions.